Skip to content

Author

M. Baboudjian

We have 4 of 275 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Prostate Cancer Patient-Derived Organoids (PDOs) as Functional Avatars for Antisense Oligonucleotide (ASO)-Based Personalized Therapy.

Patient-derived tumor organoids (PDOs) closely preserve the cellular heterogeneity, histopathology, and molecular features of the original tumors, making them powerful preclinical models. Antisense oligonucleotides (ASOs) are an emerging class of precision medicines that modulate gene expression at the RNA level with h...

Thi Thom Tran, Thi Thuc Uyen Phan, M. Baboudjian et al. · 0 citations
Editorial Oct 2026

Metastasis-free Survival in High-risk Prostate Cancer: A Valid Surrogate, but Is it Transportable Across Strategies of Unequal Systemic Exposure?

Metastasis-free survival (MFS) may not have the same meaning after radical prostatectomy (RP) and radiotherapy (RT), largely because RT is typically combined with prolonged androgen-deprivation therapy (ADT), which can delay the clinical emergence of metastases. Therefore, MFS benefits cannot be assumed to have the sam...

M. Baboudjian, Alessandro Uleri, G. Fallara et al. · 0 citations
Open access Sep 2026

A novel 5-FU derivative chemotherapy: a promising pan-cancer treatment to improve antitumor efficacy and overcome therapy resistance

Mechanistically, EB-18 exerts multifaceted antitumor effects by disrupting the HSP27/DDX5 axis and DNA damage-response machinery, promoting DNA damage and apoptosis, while suppressing AKT/mTOR prosurvival signaling.

Quang Hieu Duong, E. Khusnutdinova, T. Le et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.